Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3).

Trifiletti DM, Ballman KV, Brown PD, Anderson SK, Carrero XW, Cerhan JH, Whitton AC, Greenspoon J, Parney IF, Laack NN, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D.

Int J Radiat Oncol Biol Phys. 2019 Oct 22. pii: S0360-3016(19)33906-9. doi: 10.1016/j.ijrobp.2019.10.024. [Epub ahead of print]

PMID:
31654784
2.

Shiga toxin-producing Escherichia coli in British Columbia, 2011-2017: Analysis to inform exclusion guidelines.

Noftall K, Taylor M, Hoang L, Galanis E.

Can Commun Dis Rep. 2019 Sep 5;45(9):238-243. doi: 10.14745/ccdr.v45i09a03. eCollection 2019 Sep 5.

3.

Outbreak of Salmonella Chailey infections linked to precut coconut pieces - United States and Canada, 2017.

Luna S, Taylor M, Galanis E, Asplin R, Huffman J, Wagner D, Hoang L, Paccagnella A, Shelton S, Ladd-Wilson S, Seelman S, Whitney B, Elliot E, Atkinson R, Marshall K, Basler C.

Can Commun Dis Rep. 2018 Oct 4;44(10):264-266. doi: 10.14745/ccdr.v44i10a05. eCollection 2018 Oct 4.

4.

Climate Classification System-Based Determination of Temperate Climate Detection of Cryptococcus gattii sensu lato.

Acheson ES, Galanis E, Bartlett K, Klinkenberg B.

Emerg Infect Dis. 2019 Sep;25(9):1723-1726. doi: 10.3201/eid2509.181884.

5.

Outbreak of Escherichia coli O157:H7 Infections Linked to Mechanically Tenderized Beef and the Largest Beef Recall in Canada, 2012.

Currie A, Honish L, Cutler J, Locas A, Lavoie MC, Gaulin C, Galanis E, Tschetter L, Chui L, Taylor M, Jamieson F, Gilmour M, Ng C, Mutti S, Mah V, Hamel M, Martinez A, Buenaventura E, Hoang L, Pacagnella A, Ramsay D, Bekal S, Coetzee K, Berry C, Farber J, Team OBOTNI.

J Food Prot. 2019 Sep;82(9):1532-1538. doi: 10.4315/0362-028X.JFP-19-005.

PMID:
31414901
6.

Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology.

Cerhan JH, Anderson SK, Butts AM, Porter AB, Jaeckle K, Galanis E, Brown PD.

Neurooncol Pract. 2019 Jul;6(4):283-288. doi: 10.1093/nop/npy048. Epub 2018 Nov 24.

PMID:
31386061
7.

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.

Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, Rostami E, Gudjonsson O, Shaw BL, Cahill DP, Galanis E, Barker FG 2nd, Santagata S, Brastianos PK.

Cancer. 2019 Sep 1;125(17):2910-2914. doi: 10.1002/cncr.32197. Epub 2019 Jul 17. No abstract available.

PMID:
31314136
8.

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D.

Cancer. 2019 Nov 1;125(21):3790-3800. doi: 10.1002/cncr.32340. Epub 2019 Jul 10.

PMID:
31290996
9.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Jul 4. pii: noz119. doi: 10.1093/neuonc/noz119. [Epub ahead of print]

PMID:
31276167
10.

Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.

Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, Deyle DR, Federspiel MJ, Fielding A, Galanis E, Lacy MQ, Leibovich BC, Liu MC, Muñoz-Alía M, Miest TC, Molina JR, Mueller S, Okuno SH, Packiriswamy N, Peikert T, Raffel C, Van Rhee F, Ungerechts G, Young PR, Zhou Y, Peng KW.

Mayo Clin Proc. 2019 Sep;94(9):1834-1839. doi: 10.1016/j.mayocp.2019.05.006. Epub 2019 Jun 22. Review.

11.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186. No abstract available.

PMID:
31215634
12.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

PMID:
31175826
13.

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):583. doi: 10.1007/s11060-019-03201-3.

14.

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):573-581. doi: 10.1007/s11060-019-03194-z. Epub 2019 May 22. Erratum in: J Neurooncol. 2019 Jun 5;:.

PMID:
31119479
15.

Outbreaks of Norovirus and Acute Gastroenteritis Associated with British Columbia Oysters, 2016-2017.

Meghnath K, Hasselback P, McCormick R, Prystajecky N, Taylor M, McIntyre L, Man S, Whitfield Y, Warshawsky B, McKinley M, Bitzikos O, Hexemer A, Galanis E; Outbreak Team.

Food Environ Virol. 2019 Jun;11(2):138-148. doi: 10.1007/s12560-019-09374-4. Epub 2019 Mar 21.

PMID:
30900141
16.

Interferon signaling predicts response to oncolytic virotherapy.

Kurokawa C, Galanis E.

Oncotarget. 2019 Feb 22;10(16):1544-1545. doi: 10.18632/oncotarget.26679. eCollection 2019 Feb 22. No abstract available.

17.

A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.

Kurokawa C, Iankov ID, Galanis E.

Virus Res. 2019 Apr 2;263:145-150. doi: 10.1016/j.virusres.2019.01.014. Epub 2019 Jan 23.

PMID:
30684519
18.

Advances in multidisciplinary therapy for meningiomas.

Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i18-i31. doi: 10.1093/neuonc/noy136.

19.

New molecular targets in meningiomas: the present and the future.

Venur VA, Santagata S, Galanis E, Brastianos PK.

Curr Opin Neurol. 2018 Dec;31(6):740-746. doi: 10.1097/WCO.0000000000000615. Review.

PMID:
30379704
20.

Outbreak of Salmonella Chailey Infections Linked To Precut Coconut Pieces - United States and Canada, 2017.

Luna S, Taylor M, Galanis E, Asplin R, Huffman J, Wagner D, Hoang L, Paccagnella A, Shelton S, Ladd-Wilson S, Seelman S, Whitney B, Elliot E, Atkinson R, Marshall K, Basler C.

MMWR Morb Mortal Wkly Rep. 2018 Oct 5;67(39):1098-1100. doi: 10.15585/mmwr.mm6739a5.

21.

Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.

Galanis E, Nassiri F, Coy S, Nejad R, Zadeh G, Santagata S.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:148-157. doi: 10.1200/EDBK_200989. Review.

22.

NOTCH3 expression is linked to breast cancer seeding and distant metastasis.

Leontovich AA, Jalalirad M, Salisbury JL, Mills L, Haddox C, Schroeder M, Tuma A, Guicciardi ME, Zammataro L, Gambino MW, Amato A, Di Leonardo A, McCubrey J, Lange CA, Liu M, Haddad T, Goetz M, Boughey J, Sarkaria J, Wang L, Ingle JN, Galanis E, D'Assoro AB.

Breast Cancer Res. 2018 Sep 4;20(1):105. doi: 10.1186/s13058-018-1020-0.

23.

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):26-36. doi: 10.1093/neuonc/noy137.

PMID:
30137421
24.

Outbreak of Vibrio parahaemolyticus Associated with Consumption of Raw Oysters in Canada, 2015.

Taylor M, Cheng J, Sharma D, Bitzikos O, Gustafson R, Fyfe M, Greve R, Murti M, Stone J, Honish L, Mah V, Punja N, Hexemer A, McIntyre L, Henry B, Kendall P, Atkinson R, Buenaventura E, Martinez-Perez A, Galanis E, Team TOI.

Foodborne Pathog Dis. 2018 Sep;15(9):554-559. doi: 10.1089/fpd.2017.2415. Epub 2018 Jun 29.

PMID:
29958009
25.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132. doi: 10.1093/jnci/djy033.

26.

Surveillance for Lyme disease in Canada: 2009-2015.

Gasmi S, Ogden NH, Lindsay LR, Burns S, Fleming S, Badcock J, Hanan S, Gaulin C, Leblanc MA, Russell C, Nelder M, Hobbs L, Graham-Derham S, Lachance L, Scott AN, Galanis E, Koffi JK.

Can Commun Dis Rep. 2017 Oct 5;43(10):194-199. eCollection 2017 Oct 5.

27.

Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report.

Himes BT, Ruff MW, Van Gompel JJ, Park SS, Galanis E, Kaufmann TJ, Uhm JH.

J Neurosurg. 2018 Apr 1:1-5. doi: 10.3171/2017.11.JNS172373. [Epub ahead of print]

PMID:
29701552
28.

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053.

29.

Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells.

Ohmine S, Salisbury JL, Ingle J, Pettinato G, Haddox CL, Haddad T, Galanis E, Ikeda Y, D'assoro AB.

Oncol Rep. 2018 Apr;39(4):1725-1730. doi: 10.3892/or.2018.6239. Epub 2018 Jan 31.

30.

Outbreak of Escherichia coli O157:H7 Infections Linked to Aged Raw Milk Gouda Cheese, Canada, 2013.

Currie A, Galanis E, Chacon PA, Murray R, Wilcott L, Kirkby P, Honish L, Franklin K, Farber J, Parker R, Shyng S, Sharma D, Tschetter L, Hoang L, Chui L, Pacagnella A, Wong J, Pritchard J, Kerr A, Taylor M, Mah V, Flint J; Investigative Team.

J Food Prot. 2018 Feb;81(2):325-331. doi: 10.4315/0362-028X.JFP-17-283.

PMID:
29369688
31.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

32.

Associations between extreme precipitation and acute gastro-intestinal illness due to cryptosporidiosis and giardiasis in an urban Canadian drinking water system (1997-2009).

Chhetri BK, Takaro TK, Balshaw R, Otterstatter M, Mak S, Lem M, Zubel M, Lysyshyn M, Clarkson L, Edwards J, Fleury MD, Henderson SB, Galanis E.

J Water Health. 2017 Oct;15(6):898-907. doi: 10.2166/wh.2017.100.

PMID:
29215354
33.

Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Opyrchal M, Gil M, Salisbury JL, Goetz MP, Suman V, Degnim A, McCubrey J, Haddad T, Iankov I, Kurokawa CB, Shumacher N, Ingle JN, Galanis E, D'Assoro AB.

Oncotarget. 2017 Sep 1;8(53):91803-91816. doi: 10.18632/oncotarget.20610. eCollection 2017 Oct 31.

34.

Evaluation of Agricultural Interventions on Human and Poultry-Related Salmonella Enteritidis in British Columbia.

Taylor M, Cox W, Otterstatter M, de With N, Galanis E.

Foodborne Pathog Dis. 2018 Jan;15(1):39-43. doi: 10.1089/fpd.2017.2302. Epub 2017 Oct 13.

PMID:
29028435
35.

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF.

Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Review.

36.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

37.

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.

Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, Farace E, Cerhan JH, Anderson SK, Carrero XW, Garces YI, Barker FG 2nd, Deming R, Dixon JG, Burri SH, Chung C, Ménard C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1173-1178. doi: 10.1016/j.ijrobp.2017.07.045. Epub 2017 Aug 5.

38.

State of the art: the evolving role of RT in combined modality therapy for GBM.

Bindra RS, Galanis E, Mehta MP.

J Neurooncol. 2017 Sep;134(3):477-478. doi: 10.1007/s11060-017-2596-4. No abstract available.

39.

Countering the Consequences of Ego Depletion: The Effects of Self-Talk on Selective Attention.

Gregersen J, Hatzigeorgiadis A, Galanis E, Comoutos N, Papaioannou A.

J Sport Exerc Psychol. 2017 Jun 1;39(3):161-171. doi: 10.1123/jsep.2016-0265. Epub 2017 Sep 11.

PMID:
28891370
40.

Remote sensing measurements of sea surface temperature as an indicator of Vibrio parahaemolyticus in oyster meat and human illnesses.

Konrad S, Paduraru P, Romero-Barrios P, Henderson SB, Galanis E.

Environ Health. 2017 Aug 31;16(1):92. doi: 10.1186/s12940-017-0301-x.

41.

Self-talk effectiveness and attention.

Hatzigeorgiadis A, Galanis E.

Curr Opin Psychol. 2017 Aug;16:138-142. doi: 10.1016/j.copsyc.2017.05.014. Epub 2017 Jun 15. Review.

PMID:
28813338
42.

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D.

Lancet Oncol. 2017 Aug;18(8):1049-1060. doi: 10.1016/S1470-2045(17)30441-2. Epub 2017 Jul 4.

43.

Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma.

Domingo-Musibay E, Heun JM, Nevala WK, Callstrom M, Atwell T, Galanis E, Erickson LA, Markovic SN.

Oncologist. 2017 Sep;22(9):1026-e93. doi: 10.1634/theoncologist.2017-0060. Epub 2017 Jul 5.

44.

Evaluating the Timeliness of Enteric Disease Surveillance in British Columbia, Canada, 2012-13.

Galanis E, Taylor M, Romanowski K, Bitzikos O, Jeyes J, Nowakowski C, Stone J, Murti M, Paccagnella A, Forsting S, Li S, Hoang L.

Can J Infect Dis Med Microbiol. 2017;2017:9854103. doi: 10.1155/2017/9854103. Epub 2017 Jun 1.

45.

Extraskeletal Osteosarcoma: Outcomes and the Role of Chemotherapy.

Paludo J, Fritchie K, Haddox CL, Rose PS, Arndt CAS, Marks RS, Galanis E, Okuno SH, Robinson SI.

Am J Clin Oncol. 2018 Sep;41(9):832-837. doi: 10.1097/COC.0000000000000397.

46.

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Kunos CA, Galanis E, Buchsbaum J, Shi Q, Strauss LC, Coleman CN, Ahmed MM.

J Neurooncol. 2017 Sep;134(3):551-557. doi: 10.1007/s11060-017-2458-0. Epub 2017 May 30. Review.

47.

Searching for clues for eighteen years: Deciphering the ecological determinants of Cryptococcus gattii on Vancouver Island, British Columbia.

Acheson ES, Galanis E, Bartlett K, Mak S, Klinkenberg B.

Med Mycol. 2018 Feb 1;56(2):129-144. doi: 10.1093/mmy/myx037. Review.

PMID:
28525610
48.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

49.

Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E.

Curr Cancer Drug Targets. 2018;18(2):177-187. doi: 10.2174/1568009617666170222125035. Review.

50.

Potential and clinical translation of oncolytic measles viruses.

Robinson S, Galanis E.

Expert Opin Biol Ther. 2017 Mar;17(3):353-363. doi: 10.1080/14712598.2017.1288713. Review.

Supplemental Content

Loading ...
Support Center